kabutan

PRISM BioLab Co.,LTD(206A) Summary

206A
TSE Growth
PRISM BioLab Co.,LTD
184
JPY
+4
(+2.22%)
Apr 28, 3:30 pm JST
1.15
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
2.80
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
181 JPY 1.13 USD
Previous Close Apr 27
180 JPY 1.12 USD
High Apr 28, 3:30 pm
184 JPY 1.15 USD
Low Apr 28, 9:00 am
177 JPY 1.11 USD
Volume
136,900
Trading Value
0.03B JPY 0.16M USD
VWAP
180.98 JPY 1.14 USD
Minimum Trading Value
18,400 JPY 115 USD
Market Cap
6.80B JPY 0.04B USD
Number of Trades
142
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Slightly High
1-Year Average
470
1-Year High Dec 2, 2025
10,028
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 2,260,600
Apr 17, 2026 0 2,395,700
Apr 10, 2026 0 2,566,700
Apr 3, 2026 0 1,945,800
Mar 27, 2026 0 1,907,100
Company Profile
PRISM BioLab Co., LTD engages in the research and development of new drugs using its proprietary drug discovery platform (PepMetics technology).
Sector
Pharmaceuticals
PRISM BioLab is a research and development-oriented venture company focusing on drug discovery utilizing its proprietary PepMetics technology platform. The company is dedicated to creating small molecule drugs targeting intracellular protein-protein interactions (PPIs). By leveraging its unique compound library and synthesis techniques, PRISM BioLab has overcome the challenges associated with traditional approaches, which often resulted in large molecular weight compounds with potential side effects. The company's innovative small molecule compounds have successfully cleared these hurdles, enabling the development of PPI inhibitors. PRISM BioLab has multiple pipelines, including Wnt inhibitors and translation control agents, and pursues both in-house development and collaborative projects with pharmaceutical companies. By pioneering the new drug discovery field of intracellular PPIs, PRISM BioLab aims to create innovative pharmaceuticals for diseases that currently lack effective treatments.